Literature DB >> 18594826

Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival.

Axel S Merseburger1, Mario W Kramer, Jörg Hennenlotter, Jürgen Serth, Stephan Kruck, Alfredo Gracia, Arnulf Stenzl, Markus A Kuczyk.   

Abstract

OBJECTIVES: Galectin-3 is a member of the glycoprotein family, actively involved in various biological interactions including cell growth, cell adhesion, cell differentiation and apoptosis. The aim of this study was to analyze the expression of galectin-3 in clear cell renal carcinoma and to assess its prognostic significance.
METHODS: The expression of galectin-3 was analyzed by immunohistochemistry in 149 clear cell renal carcinomas. The levels were correlated to established clinical parameters such as nuclear grade, pathological stage, lymph node, distant metastasis, and patients' survival.
RESULTS: In normal kidney tissue, the expression of galectin-3 was found to be uniformly present in the tubular epithelial cells. A decrease of antigen expression levels were significantly associated with higher T-stages (P < 0.02), unfavourable long-term prognosis in univariate Kaplan-Meier (P < 0.007) and multivariate Cox proportional hazard analyses (P < 0.04). Univariate analysis could demonstrate an association with tumor-specific death with decreased galectin-3 expression, whereas multivariate analysis failed to prove the aforementioned observation.
CONCLUSION: Our results suggest that a loss of galectin-3 expression is involved in renal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594826     DOI: 10.1007/s00345-008-0294-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

1.  Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.

Authors:  D K Hsu; C A Dowling; K C Jeng; J T Chen; R Y Yang; F T Liu
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

Review 2.  Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

Authors:  Gabriel A Rabinovich; Linda G Baum; Nicola Tinari; Roberto Paganelli; Clara Natoli; Fu Tong Liu; Stefano Iacobelli
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

3.  Decreased expression of galectin-3 is associated with progression of human breast cancer.

Authors:  V Castronovo; F A Van Den Brûle; P Jackers; N Clausse; F T Liu; C Gillet; M E Sobel
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

4.  The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers.

Authors:  G Choufani; N Nagy; S Saussez; H Marchant; P Bisschop; M Burchert; A Danguy; S Louryan; I Salmon; H J Gabius; R Kiss; S Hassid
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

Review 5.  Tissue microarrays in clinical urology--technical considerations.

Authors:  Mario W Kramer; Axel S Merseburger; Jorg Hennenlotter; Markus Kuczyk
Journal:  Scand J Urol Nephrol       Date:  2007

6.  Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.

Authors:  F A van den Brûle; D Waltregny; F T Liu; V Castronovo
Journal:  Int J Cancer       Date:  2000-07-20       Impact factor: 7.396

7.  Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas.

Authors:  Takeshi Shimamura; Michiie Sakamoto; Yoshinori Ino; Kazuaki Shimada; Tomoo Kosuge; Yasuto Sato; Katsuaki Tanaka; Hisahiko Sekihara; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

8.  Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3.

Authors:  Stéphane Califice; Vincent Castronovo; Marc Bracke; Frédéric van den Brûle
Journal:  Oncogene       Date:  2004-09-30       Impact factor: 9.867

9.  Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death.

Authors:  H P Hahn; M Pang; J He; J D Hernandez; R-Y Yang; L Y Li; X Wang; F-T Liu; L G Baum
Journal:  Cell Death Differ       Date:  2004-12       Impact factor: 15.828

Review 10.  [Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma].

Authors:  A S Merseburger; J Hennenlotter; D Schilling; K D Sievert; R Küfer; M A Kuczyk
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

View more
  14 in total

1.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

Review 2.  [Current state of systemic therapy of metastatic renal cell carcinoma].

Authors:  A S Merseburger; S Waalkes; M A Kuczyk
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

3.  Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence.

Authors:  Judith S Knapp; Soum D Lokeshwar; Ulrich Vogel; Jörg Hennenlotter; Christian Schwentner; Mario W Kramer; Arnulf Stenzl; Axel S Merseburger
Journal:  World J Urol       Date:  2012-08-15       Impact factor: 4.226

4.  Predictive importance of galectin-3 for recurrence of non-small cell lung cancer.

Authors:  Yoko Kataoka; Tomoyuki Igarashi; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-03-22

5.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

6.  Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer.

Authors:  Mario W Kramer; Sandra Waalkes; Jörg Hennenlotter; Jürgen Serth; Arnulf Stenzl; Markus A Kuczyk; Axel S Merseburger
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

7.  Antitumor effects of galectin-3 inhibition in human renal carcinoma cells.

Authors:  Yangyang Xu; Changfu Li; Jiahang Sun; Jingshu Li; Xin Gu; Wanhai Xu
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-03

Review 8.  Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples.

Authors:  Hafiz Ahmed
Journal:  Biomark Cancer       Date:  2010-02-18

9.  Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma.

Authors:  Tamara Straube; Alexandra F Elli; Christoph Greb; Axel Hegele; Hans-Peter Elsässer; Delphine Delacour; Ralf Jacob
Journal:  J Exp Clin Cancer Res       Date:  2011-09-29

10.  Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma.

Authors:  Christoph-A von Klot; Mario W Kramer; Inga Peters; Joerg Hennenlotter; Mahmoud Abbas; Ralph Scherer; Thomas Rw Herrmann; Arnulf Stenzl; Markus A Kuczyk; Juergen Serth; Axel S Merseburger
Journal:  BMC Clin Pathol       Date:  2014-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.